文献速递糖尿病

用抗糖尿病药物降低2型糖尿病心血管风险:EMPA-REG OUTCOME、LEADER和SUSTAIN-6试验主要心血管结局结果综述

Mitigating Cardiovascular Risk in Type 2 Diabetes With Antidiabetes Drugs: A Review of Principal Cardiovascular Outcome Results of EMPA-REG OUTCOME, LEADER, and SUSTAIN-6 Trials.
PubMed 文献 · Diabetes Care · 2017-01-01

已公布的七项试验均显示主要不良心血管事件(MACE)非劣效,其中恩格列净和利拉鲁肽显著降低MACE、心血管死亡和全因死亡风险,司美格鲁肽显著降低MACE但不降低死亡风险;这些效应与血糖控制差异不成比例。

要点

  • 恩格列净和利拉鲁肽均显著降低MACE、心血管死亡和全因死亡风险(与安慰剂比)。
  • 司美格鲁肽显著降低MACE,但不降低心血管死亡或全因死亡风险(与安慰剂比)。
  • 七项试验均显示MACE非劣效,但仅三项显示心血管获益;效应与血糖差异不成比例。

核心结论

  • 总体而言,这些试验结果为这些疗法在降低2型糖尿病患者心血管风险方面带来了有利的获益-风险平衡。
  • 需要更多研究来阐明潜在机制,并确认心血管获益是类别效应,还是在不合并已确诊心血管疾病的患者中持续存在,或甚至在没有糖尿病的患者中也明显。

研究设计与样本

  • 美国食品药品监督管理局(FDA)2008年发布糖尿病指南,要求所有新抗糖尿病药物排除超额心血管风险,定义为主要不良心血管事件(MACE)双侧95%CI上限在批准前小于1.80、批准后小于1.30。
  • 根据该指南,迄今已完成或正在进行超过25项大型前瞻性随机对照临床试验,涉及近195,000名受试者。
  • 目前已公布七项试验结果:三项使用二肽基肽酶4抑制剂,一项使用钠-葡萄糖协同转运蛋白2(SGLT2)抑制剂,三项使用胰高血糖素样肽1受体激动剂(GLP-1 RA)。

主要发现

  • 七项试验均显示,与安慰剂相比,这些药物的MACE发生率非劣效。
  • 恩格列净(SGLT2抑制剂)和利拉鲁肽(GLP-1 RA)治疗均显著降低MACE风险、心血管原因死亡风险和任何原因死亡风险(与安慰剂相比)。
  • 司美格鲁肽(另一种GLP-1 RA)显示MACE发生率显著降低,但心血管原因死亡或任何原因死亡风险未显著降低(与安慰剂相比)。
  • 在所有试验中,治疗对结局的影响与血糖控制水平的微小差异不成比例,提示观察到的效应可能与非降糖疗效差异无关。

局限性

  • 需要更多研究来阐明潜在机制,并确认心血管获益是类别效应,还是在不合并已确诊心血管疾病的患者中持续存在,或甚至在没有糖尿病的患者中也明显。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The U.S. Food and Drug Administration (FDA) issued a diabetes guidance in 2008 mandating that all new antidiabetes drugs rule out excess cardiovascular (CV) risk, defined as an upper bound of the two-sided 95% CI for major adverse CV events (MACE) of less than 1.80 preapproval and 1.30 postapproval. Over 25 large, prospective, randomized, controlled clinical trials involving nearly 195,000 subjects thus far have been completed or are ongoing in accordance with this guidance. The results of seven trials have been presented so far-three with dipeptidyl peptidase 4 inhibitors, one with a sodium-glucose cotransporter 2 (SGLT2) inhibitor, and three with glucagon-like peptide 1 receptor agonists (GLP-1 RA). While all seven trials showed noninferiority in the rate of MACE with the use of these agents compared with placebo, three of them revealed CV benefits. Treatment with empagliflozin (an SGLT2 inhibitor) and treatment with liraglutide (a GLP-1 RA) both significantly reduced the risk of MACE, mortality from CV causes, and mortality from any cause when compared with placebo. Treatment with semaglutide, another GLP-1 RA, showed a significantly lower rate of MACE but not mortality from CV or any cause compared with placebo. In all of the trials, the effects of treatment on outcomes were out of proportion to the small differences in glycemic control levels, suggesting that the effects observed were likely unrelated to differences in the glucose-lowering efficacy. Overall, the results of these trials yield a favorable benefit-risk balance for these therapies in mitigating CV risk in patients with type 2 diabetes. More research is needed to elucidate the underlying mechanisms and confirm whether the CV benefits are a class effect or whether the benefits persist in patients without established CV disease or are evident even in patients without diabetes.

来源:Diabetes Care,查看原文。版权归原作者所有。

引用

  1. Kaul S. Mitigating Cardiovascular Risk in Type 2 Diabetes With Antidiabetes Drugs: A Review of Principal Cardiovascular Outcome Results of EMPA-REG OUTCOME, LEADER, and SUSTAIN-6 Trials. Diabetes Care. 2017. PMID: 28637887. doi:10.2337/dc17-0291

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。